A 2017 article in The New England Journal of Medicine details the results of a randomized clinical trial designed to evaluate the efficacy of a rotavirus gastroenteritis vaccine designed for infants. As per the authors:“Each year, rotavirus gastroenteritis is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in sub-Saharan Africa. We conducted a randomized, placebo-controlled trial in Niger to evaluate the efficacy of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV, Serum Institute of India) to prevent severe rotavirus gastroenteritis. Healthy infants received three doses of the vaccine or placebo at 6, 10, and 14 weeks of age. Episodes of rotavirus gastroenteritis were assessed through active and passive surveillance.”The following Kaplan-Meier curves show the time to a diagnosis of rotavirus gastroenteritis separately for the vaccine and placebo samples. Infants were followed for up to 60 weeks after receiving the third dose of the vaccine (or placebo), until they either developed rotavirus gastroenteritis or were censored (lost to follow-up, or still rotavirus gastroenteritis free after 60 weeks from randomization). Which of the following statements is the proper interpretation of the result regarding the IRR of rotavirusgastroenteritis for the vaccine cohort compared to the control cohort, and its 95% confidence interval?Infants in the vaccine cohort had a 33% greater risk of rotavirus gastroenteritis relative to infants in the controlcohort. This increased risk is not explained by random sampling variability as the 95% confidence interval does notinclude 0.Infants in the vaccine cohort had a 336 greater risk of rotavirus gastroenteritis relative to infants in the controlcohort. This increased risk is not explained by random sampling variability as the 95% confidence interval does notinclude 1.Infants in the vaccine cohort had a 33% lower risk of rotavirus gastroenteritis relative to infants in the controlcohort. This decreased risk is not explained by random sampling variability as the 95% confidence interval does notinclude 0.Infants in the vaccine cohort had a 33% lower risk of rotavirus gastroenteritis relative to infants in the controlcohort. This decreased risk is not explained by random sampling variability as the 95% confidence interval does notinclude 1. 100-100-80-Vaccine98니60어96-Placebo94-40-92니90-20-102030405060102030405060WeekNo. at RiskVaccine20442012196417671500142913261326Placebo20471990191616761148662The incidence rate ratio (and 95% confidence interval) of rotavirus gastroenteritis for the vaccine group compared to theplacebo group is 0.67 (0.55, 0.82)Freedom from Severe RotavirusGastroenteritis (%)

Name: A 2017 article in The New England Journal of Medicine details the resu
Uploaded: 2024-03-20T07:07:00.000Z
Channel: Bartleby
Description: A 2017 article in The New England Journal of Medicine details the results of a randomized clinical trial designed to evaluate the efficacy of a rotavirus gastroenteritis vaccine designed for infants. As per the authors:“Each year, rotavirus gastroent

From graph it can be seen that 95% confidence interval does not include zero.So, Option (2) and…

Answered: Which of the following statements is…

MATLAB: An Introduction with Applications

6th Edition

ISBN:9781119256830

Author:Amos Gilat

Publisher:Amos Gilat

Chapter1: Starting With Matlab

Section: Chapter Questions

Problem 1P

See similar textbooks

Related questions

Concept explainers

Topic Video

Question

A 2017 article in The New England Journal of Medicine details the results of a randomized clinical trial designed to evaluate the efficacy of a rotavirus gastroenteritis vaccine designed for infants. As per the authors:

“Each year, rotavirus gastroenteritis is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in sub-Saharan Africa. We conducted a randomized, placebo-controlled trial in Niger to evaluate the efficacy of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV, Serum Institute of India) to prevent severe rotavirus gastroenteritis. Healthy infants received three doses of the vaccine or placebo at 6, 10, and 14 weeks of age. Episodes of rotavirus gastroenteritis were assessed through active and passive surveillance.”

The following Kaplan-Meier curves show the time to a diagnosis of rotavirus gastroenteritis separately for the vaccine and placebo samples. Infants were followed for up to 60 weeks after receiving the third dose of the vaccine (or placebo), until they either developed rotavirus gastroenteritis or were censored (lost to follow-up, or still rotavirus gastroenteritis free after 60 weeks from randomization).

Which of the following statements is the proper interpretation of the result regarding the IRR of rotavirus
gastroenteritis for the vaccine cohort compared to the control cohort, and its 95% confidence interval?
Infants in the vaccine cohort had a 33% greater risk of rotavirus gastroenteritis relative to infants in the control
cohort. This increased risk is not explained by random sampling variability as the 95% confidence interval does not
include 0.
Infants in the vaccine cohort had a 336 greater risk of rotavirus gastroenteritis relative to infants in the control
cohort. This increased risk is not explained by random sampling variability as the 95% confidence interval does not
include 1.
Infants in the vaccine cohort had a 33% lower risk of rotavirus gastroenteritis relative to infants in the control
cohort. This decreased risk is not explained by random sampling variability as the 95% confidence interval does not
include 0.
Infants in the vaccine cohort had a 33% lower risk of rotavirus gastroenteritis relative to infants in the control
cohort. This decreased risk is not explained by random sampling variability as the 95% confidence interval does not
include 1.

100-
100-
80-
Vaccine
98니
60어
96-
Placebo
94-
40-
92니
90-
20-
10
20
30
40
50
60
10
20
30
40
50
60
Week
No. at Risk
Vaccine
2044
2012
1964
1767
1500
1429
1326
1326
Placebo
2047
1990
1916
1676
1148
662
The incidence rate ratio (and 95% confidence interval) of rotavirus gastroenteritis for the vaccine group compared to the
placebo group is 0.67 (0.55, 0.82)
Freedom from Severe Rotavirus
Gastroenteritis (%)

Expert Solution

Trending now

This is a popular solution!

Step by step

Solved in 3 steps

SEE SOLUTION Check out a sample Q&A here

Knowledge Booster

$Hypothesis Tests and Confidence Intervals for Proportions$

Learn more about

Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, statistics and related others by exploring similar questions and additional content below.